Analyst Price Targets — ASND
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 5, 2026 9:18 pm | — | Jefferies | $262.00 | $237.35 | StreetInsider | Ascendis Pharma (ASND) PT Raised to $262 at BofA Securities |
| March 4, 2026 8:22 pm | Alex Thompson | Stifel Nicolaus | $332.00 | $241.38 | StreetInsider | Ascendis Pharma (ASND) PT Raised to $332 at Stifel |
| March 2, 2026 3:59 pm | Kalpit Patel | Wolfe Research | $260.00 | $231.46 | StreetInsider | Ascendis Pharma (ASND) PT Raised to $260 at Wolfe Research |
| March 2, 2026 3:38 pm | Li Watsek | Cantor Fitzgerald | $300.00 | $231.43 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND) |
| March 2, 2026 3:03 pm | Josh Schimmer | Evercore ISI | $324.00 | $234.07 | StreetInsider | Ascendis Pharma (ASND) PT Raised to $324 at Evercore ISI |
| March 2, 2026 9:55 am | Paul Choi | Goldman Sachs | $255.00 | $233.50 | StreetInsider | Ascendis Pharma (ASND) PT Raised to $255 at Goldman Sachs |
| February 12, 2026 1:58 pm | — | Wedbush | $273.00 | $218.39 | TheFly | Ascendis Pharma price target raised to $273 from $240 at Wedbush |
| February 12, 2026 1:35 pm | — | Oppenheimer | $262.00 | $217.93 | TheFly | Ascendis Pharma price target raised to $262 from $246 at Oppenheimer |
| February 12, 2026 1:20 pm | Alex Thompson | Stifel Nicolaus | $325.00 | $218.04 | TheFly | Ascendis Pharma price target raised to $325 from $256 at Stifel |
| February 12, 2026 12:42 pm | Maxwell Skor | Morgan Stanley | $256.00 | $221.49 | TheFly | Ascendis Pharma price target raised to $256 from $250 at Morgan Stanley |
Latest News for ASND
Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Ascendis Pharma secured FDA approval for Yuviwel in achondroplasia, despite ongoing legal challenges from BioMarin. I expect Yuviwel's U.S. sales to be modest, with stronger international growth potential starting next year, but also meaningful competition from BridgeBio's infigratinib. The Yuviwel and Skytrofa combination demonstrates superior efficacy, positioning ASND for potential blockbuster sales in…
American Century Companies Inc. lifted its stake in shares of Ascendis Pharma A/S (NASDAQ: ASND) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 544,606 shares of the biotechnology company's stock after purchasing an additional 13,797 shares during the
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript
COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ASND.
Senate Trading
No Senate trades found for ASND.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.